Navigation Links
MDA's Augie's Quest Expands Testing of Potential ALS Therapeutics With New $2 Million Grant to ALS TDI
Date:3/1/2011

been used as the basis for two separate international standards of practice guidelines.  In addition, the partnership has funded the acquisition of nearly a million dollars of capital equipment at the Institute, which has been used to complete major gene expression studies aimed at discovering new molecular pathways related to disease onset and progression.  In addition to funding portions of those efforts at ALS TDI, the MDA grants have also directly supported the Institute's robust preclinical therapeutic screening program.  The Institute is advancing one of these potential therapies, ALS TDI 00846, toward the clinic for evaluation in people living with the disease today.  

"Our relationship with ALS TDI is producing tangible results for the worldwide ALS community.  This fast-track effort is altering the way researchers advance potential treatments for ALS and has helped many labs evaluate candidate therapeutics quicker and more efficiently than before, " said R. Rodney Howell, M.D., Chairman of the MDA Board of Directors.

This new grant from MDA's Augie's Quest will fund several projects at ALS TDI, including the screening of at least three potential therapeutics targeting novel pathways identified by the Institute.  In addition, a portion of the funding received from MDA's Augie's Quest will fund the Institute's efforts to characterize TDP-43 mouse model, an emerging model of neurodegeneration that has been related to ALS and other neurodegenerative diseases. Portions of other technology development projects around gene therapy and RNAi are also funded under the terms of the renewed grant from MDA's Augie's Quest.

"It is humbling to have the MDA continue its support of ALS TDI at such an enormous level.  It is a testament to the efficiency and innovativeness of the multi-disciplinary team working at the Institute today.  This grant will provide crucial new resources that we desperately need t
'/>"/>

SOURCE ALS Therapy Development Foundation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Quest Diagnostics to Acquire Athena Diagnostics, Establishing Leading Position in Rapidly Growing Neurology Testing Market
2. Questcor Pharmaceuticals to Be Added to S&P SmallCap 600 Index
3. Quest Diagnostics® Care360™ EHR Receives ONC-ATCB 2011/2012 Certification
4. Quest Diagnostics Increases Share Repurchase Authority By $250 Million
5. Questcor Announces Third Quarter 2010 Earnings Release Date and Conference Call
6. GeneGo Announces Integration With GenomeQuest for Pathway Analysis of Next Generation Sequencing Data
7. ASEBIO Requests the Alignment of Spain With the European Unions Future Strategy of Bioeconomy
8. SciQuest Makes the Inc. 500
9. 5000 List of Fastest-Growing Companies for Fourth Consecutive Year
10. New resource examines questions about the role of nanoscience
11. Quest PharmaTech Announces Formation of Clinical Advisory Panel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... MA and Pittsburgh PA (PRWEB) September 30, 2014 ... Clinical Research Nurses ( IACRN), a non-profit ... Alliance for Clinical Research Excellence and Safety ... the signing of a strategic alliance agreement, setting ... IACRN’s vision is to enhance clinical research quality ...
(Date:9/29/2014)... forefront of diagnostics today, with imaging techniques like ... and NMR (nuclear magnetic resonance) increasing steeply over ... image resolution and quality still limit these techniques ... solution is hyperpolarization, which involves injecting the patient ... following the distribution and fate of specific molecules ...
(Date:9/29/2014)... , Sept. 29, 2014  Ten of the ... of cartilage repair, regeneration, allograft reconstruction and research ... the world gathered to discuss the future of ... of Regenerative Medicine symposium, Cartilage Regeneration: State ... included Orthopedic Biosurgery, Minced Juvenile Allograft, and State ...
(Date:9/29/2014)... , Sept. 29, 2014 /PRNewswire/ - Portage Biotech Inc. ... PBT.U), is pleased to announce that its three Promissory ... Portage, who advanced $ 100,000 each in July 2014 ... their Notes and related Coupons converted into 3,500,001 restricted ... carried 5% coupon. Both the Note and the coupon ...
Breaking Biology Technology:IACRN and ACRES to Support Clinical Research Nurses 2IACRN and ACRES to Support Clinical Research Nurses 3A safer approach for diagnostic medical imaging 2A safer approach for diagnostic medical imaging 3World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3Portage announces conversion of its debt into equity 2Portage announces conversion of its debt into equity 3
... and Clinical Studies Demonstrate Activity of ... Agent against Gram-Positive Bacteria, CHICAGO, Sept. 18 ... THRX ) announced today results with the,investigational ... skin and skin structure infections,(cSSSIs) from a controlled ...
... Preclinical Animal Data Demonstrates Selective Survival Advantage of ... ZFN-Treated Immune Cells after HIV Infection, ... (Nasdaq: SGMO ) announced today the presentation of ... resistant to,HIV infection by treatment with zinc finger DNA-binding ...
... Research - the New ISI Web of Knowledge - ... Institutions Throughout the Country, PHILADELPHIA and LONDON, Sept. ... TOC ; TSX: TOC) and,leading provider of information ... that Spain,s La Fundacion Espanola,para la Ciencia y la ...
Cached Biology Technology:Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 2Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 3Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 4Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 5Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC 6Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 2Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 3Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 4Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 5Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge 2Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge 3
(Date:9/29/2014)... , Sept. 29, 2014 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... S. Miceli has been named the Company,s Vice-President ... Gino Pereira as Chief Financial Officer. Mr. ... Executive Officer and as a Director. Mr. ...
(Date:9/29/2014)... safely tolerate treatment with cells cultured from human placental ... journal Multiple Sclerosis and Related Disorders . The ... conducted by researchers at Mount Sinai, Celgene Cellular Therapeutics ... institutions. , While designed to determine safety of ... that a preparation of cultured cells called PDA-001 may ...
(Date:9/28/2014)... by scientists at the University of California, Santa Cruz, ... within the genomes of primates drove the evolution of ... in every cell of our bodies. , The ... "retrotransposons" (a.k.a. "jumping genes") and the genes that have ... have, for the first time, identified genes in humans ...
Breaking Biology News(10 mins):NXT-ID, Inc. Names Vice-President and Chief Financial Officer 2NXT-ID, Inc. Names Vice-President and Chief Financial Officer 3Cells from placentas safe for patients with multiple sclerosis 2Human genome was shaped by an evolutionary arms race with itself 2Human genome was shaped by an evolutionary arms race with itself 3Human genome was shaped by an evolutionary arms race with itself 4
... is well known that animals use song as a way ... developed an unusual way of scaring off predators ?by singing ... Andrews discovered that wild gibbons in Thailand have developed a ... singing for survival, the gibbons appear to use the song ...
... replication within resident immune cells of the testis, providing ... even after effective highly active antiretroviral therapy. The related ... to human immunodeficiency virus-1 infection in situ and in ... of Pathology. , According to the most recent ...
... timing of food availability, researchers have identified the first ... Period 2, is a key component of the circadian ... of the University of Fribourg and Etienne Challet of ... 24th issue of the journal Current Biology, published by ...
Cached Biology News:Singing for survival 2Singing for survival 3Human testis harbors HIV-1 in resident immune cells 2Circadian gene helps the brain predict mealtime 2
... operational costs. More efficient interfacing with ... sample volumes. Industry demands for benefits ... microbore chromatography for routine applications. Standard ... satisfy the need to operate with ...
From the company that first brought you the chromatin immunoprecipitation (ChIP) kit, a new and improved kit, EZ-ChIP, is now available to make your experiments easier, quicker, and most importantly,...
... Hepta adaptor for the PDS-1000 He biolistic system ... than the standard system. It fits into the ... it splits the helium shock wave over 7 ... tungsten particles over this larger area, the system ...
Kit Components: Anti-Acetylated Histone H3 Salmon Sperm DNA/Protein A Agarose All necessary buffers. ...
Biology Products: